Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Bisulfite-converted duplexes for the strand-specific detection and quantification of rare mutations.

Mattox AK, Wang Y, Springer S, Cohen JD, Yegnasubramanian S, Nelson WG, Kinzler KW, Vogelstein B, Papadopoulos N.

Proc Natl Acad Sci U S A. 2017 May 2;114(18):4733-4738. doi: 10.1073/pnas.1701382114. Epub 2017 Apr 17.

2.

Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing.

Won HH, Scott SN, Brannon AR, Shah RH, Berger MF.

J Vis Exp. 2013 Oct 18;(80):e50710. doi: 10.3791/50710.

4.

Simple multiplexed PCR-based barcoding of DNA for ultrasensitive mutation detection by next-generation sequencing.

Ståhlberg A, Krzyzanowski PM, Egyud M, Filges S, Stein L, Godfrey TE.

Nat Protoc. 2017 Apr;12(4):664-682. doi: 10.1038/nprot.2017.006. Epub 2017 Mar 2.

PMID:
28253235
5.

Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens.

Zon G, Barker MA, Kaur P, Groshen S, Jones LW, Imam SA, Boyd VL.

Anal Biochem. 2009 Sep 15;392(2):117-25. doi: 10.1016/j.ab.2009.06.001. Epub 2009 Jun 6.

PMID:
19505431
6.

Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.

Tothill RW, Li J, Mileshkin L, Doig K, Siganakis T, Cowin P, Fellowes A, Semple T, Fox S, Byron K, Kowalczyk A, Thomas D, Schofield P, Bowtell DD.

J Pathol. 2013 Dec;231(4):413-23. doi: 10.1002/path.4251.

PMID:
24037760
7.

Bisulfite Patch PCR enables multiplexed sequencing of promoter methylation across cancer samples.

Varley KE, Mitra RD.

Genome Res. 2010 Sep;20(9):1279-87. doi: 10.1101/gr.101212.109. Epub 2010 Jul 13.

8.

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.

Kim ST, Lee WS, Lanman RB, Mortimer S, Zill OA, Kim KM, Jang KT, Kim SH, Park SH, Park JO, Park YS, Lim HY, Eltoukhy H, Kang WK, Lee WY, Kim HC, Park K, Lee J, Talasaz A.

Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465.

9.

Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.

Sie D, Snijders PJ, Meijer GA, Doeleman MW, van Moorsel MI, van Essen HF, Eijk PP, Grünberg K, van Grieken NC, Thunnissen E, Verheul HM, Smit EF, Ylstra B, Heideman DA.

Cell Oncol (Dordr). 2014 Oct;37(5):353-61. doi: 10.1007/s13402-014-0196-2. Epub 2014 Sep 11.

PMID:
25209392
10.

Analyzing the cancer methylome through targeted bisulfite sequencing.

Lee EJ, Luo J, Wilson JM, Shi H.

Cancer Lett. 2013 Nov 1;340(2):171-8. doi: 10.1016/j.canlet.2012.10.040. Epub 2012 Nov 28. Review.

11.

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, Chandramohan R, Liu ZY, Won HH, Scott SN, Brannon AR, O'Reilly C, Sadowska J, Casanova J, Yannes A, Hechtman JF, Yao J, Song W, Ross DS, Oultache A, Dogan S, Borsu L, Hameed M, Nafa K, Arcila ME, Ladanyi M, Berger MF.

J Mol Diagn. 2015 May;17(3):251-64. doi: 10.1016/j.jmoldx.2014.12.006. Epub 2015 Mar 20.

12.

Detection and quantification of rare mutations with massively parallel sequencing.

Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B.

Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9530-5. doi: 10.1073/pnas.1105422108. Epub 2011 May 17.

13.

Targeted sequencing of both DNA strands barcoded and captured individually by RNA probes to identify genome-wide ultra-rare mutations.

Wang Q, Wang X, Tang PS, O'leary GM, Zhang M.

Sci Rep. 2017 Jun 13;7(1):3356. doi: 10.1038/s41598-017-03448-8.

14.

DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight.

Weisenberger DJ, Trinh BN, Campan M, Sharma S, Long TI, Ananthnarayan S, Liang G, Esteva FJ, Hortobagyi GN, McCormick F, Jones PA, Laird PW.

Nucleic Acids Res. 2008 Aug;36(14):4689-98. doi: 10.1093/nar/gkn455. Epub 2008 Jul 15.

15.

Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing.

Li Z, Guo X, Tang L, Peng L, Chen M, Luo X, Wang S, Xiao Z, Deng Z, Dai L, Xia K, Wang J.

Tumour Biol. 2016 Oct;37(10):13111-13119. Epub 2016 Jul 23.

PMID:
27449045
16.

Next-generation sequencing is highly sensitive for the detection of beta-catenin mutations in desmoid-type fibromatoses.

Aitken SJ, Presneau N, Kalimuthu S, Dileo P, Berisha F, Tirabosco R, Amary MF, Flanagan AM.

Virchows Arch. 2015 Aug;467(2):203-10. doi: 10.1007/s00428-015-1765-0. Epub 2015 Apr 3.

PMID:
25838078
17.

Multiplex amplification coupled with COLD-PCR and high resolution melting enables identification of low-abundance mutations in cancer samples with low DNA content.

Milbury CA, Chen CC, Mamon H, Liu P, Santagata S, Makrigiorgos GM.

J Mol Diagn. 2011 Mar;13(2):220-32. doi: 10.1016/j.jmoldx.2010.10.008.

18.

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.

Ihle MA, Fassunke J, König K, Grünewald I, Schlaak M, Kreuzberg N, Tietze L, Schildhaus HU, Büttner R, Merkelbach-Bruse S.

BMC Cancer. 2014 Jan 10;14:13. doi: 10.1186/1471-2407-14-13.

19.

COLD-PCR enrichment of rare cancer mutations prior to targeted amplicon resequencing.

Milbury CA, Correll M, Quackenbush J, Rubio R, Makrigiorgos GM.

Clin Chem. 2012 Mar;58(3):580-9. doi: 10.1373/clinchem.2011.176198. Epub 2011 Dec 21.

20.

Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.

Borràs E, Jurado I, Hernan I, Gamundi MJ, Dias M, Martí I, Mañé B, Arcusa A, Agúndez JA, Blanca M, Carballo M.

BMC Cancer. 2011 Sep 24;11:406. doi: 10.1186/1471-2407-11-406.

Supplemental Content

Support Center